The Antibody Grind Has an AI Fix Now

Bayer embeds Cradle's AI platform into its antibody pipeline to cut optimization cycles and speed candidates to the clinic

24 Mar 2026

The way antibody drugs are discovered just got smarter. On January 7, 2026, Bayer and Amsterdam-based Cradle announced a three-year collaboration placing generative AI at the center of Bayer's therapeutic antibody pipeline, with one goal: faster, more efficient routes to clinical-grade drug candidates.

The problem Cradle is solving is one every biologics developer knows well. Building an effective antibody means running repeated lab cycles to fine-tune potency, safety, and manufacturability, and each iteration burns time and money. Cradle's platform compresses that process by learning from experimental data in real time, helping scientists make sharper design decisions earlier and cutting the number of optimization rounds needed to reach a viable candidate.

Bayer is embedding the platform directly into its existing R&D workflows, giving antibody scientists access to Cradle's design, test, and optimization tools from within their standard systems. A joint machine learning research project will run alongside the deployment, pushing the platform's capabilities further. Bayer's antibody pipeline spans cardiovascular, oncology, immunology, and neurodegenerative diseases, and the company sees AI-driven optimization as essential to growing that portfolio without a proportional rise in wet-lab workload.

The deal landed during a defining stretch for the pharma-AI sector. January 2026 brought a cluster of similar platform agreements, signaling that AI has moved from experimental tool to core R&D infrastructure across the industry. Cradle already works with six of the top 25 global pharmaceutical companies and is active across more than 50 programs, a track record that anchors its enterprise positioning.

Cradle CEO Stef van Grieken has spoken of a shift in what drug discovery organizations now demand: platforms that scale across portfolios and teams, not narrow tools tied to a single asset. For Bayer, the partnership is a structural investment in the speed and quality of its biologics pipeline. For the broader sector, it is a clear signal that the deployment era has arrived. The clinic will deliver the final verdict, but with platforms of this scale now embedded across major pipelines, the industry is better placed than ever to move from molecule to medicine.